Literature DB >> 30228501

New Pharmacologic Agents for Diabetes Treatment.

Sarah Bou Malham1, Cynthia J Herrick2.   

Abstract

Therapeutic options for diabetes management have expanded dramatically in the last five years. While there continues to be consensus that lifestyle modification aimed at 5-7% weight loss and metformin are the appropriate first line therapies for type 2 diabetes, there are many options for intensification of diabetes management. The American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE) have released recent guidelines that prioritize use of the newer classes of medications.1,2 There are a number of considerations in selecting medications, including risk of hypoglycemia, effect on body weight, adverse event profile, renal function, and cost/insurance coverage. The objective of this article is to discuss mechanism, efficacy, and safety for each new class of medications. We conclude with a quick reference for the use of these medications in primary and specialty care, based on their various attributes and patient and provider preferences.

Entities:  

Year:  2016        PMID: 30228501      PMCID: PMC6139836     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  37 in total

1.  Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.

Authors:  T Heise; L Nosek; S G Bøttcher; H Hastrup; H Haahr
Journal:  Diabetes Obes Metab       Date:  2012-07-10       Impact factor: 6.577

2.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

Review 3.  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Authors:  Despoina Vasilakou; Thomas Karagiannis; Eleni Athanasiadou; Maria Mainou; Aris Liakos; Eleni Bekiari; Maria Sarigianni; David R Matthews; Apostolos Tsapas
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

4.  Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials.

Authors:  A S Abbas; H-M Dehbi; K K Ray
Journal:  Diabetes Obes Metab       Date:  2015-12-23       Impact factor: 6.577

5.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

Authors:  M A Nauck; U Niedereichholz; R Ettler; J J Holst; C Orskov; R Ritzel; W H Schmiegel
Journal:  Am J Physiol       Date:  1997-11

6.  Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Authors:  John B Buse; Michael Nauck; Thomas Forst; Wayne H-H Sheu; Sylvia K Shenouda; Cory R Heilmann; Byron J Hoogwerf; Aijun Gao; Marilyn K Boardman; Mark Fineman; Lisa Porter; Guntram Schernthaner
Journal:  Lancet       Date:  2012-11-07       Impact factor: 79.321

7.  Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

Authors:  Bruce Neal; Vlado Perkovic; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Peter Stein; Mehul Desai; Wayne Shaw; Joel Jiang; Frank Vercruysse; Gary Meininger; David Matthews
Journal:  Am Heart J       Date:  2013-06-24       Impact factor: 4.749

8.  A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.

Authors:  Tim Heise; Cees J Tack; Robert Cuddihy; Jaime Davidson; Didier Gouet; Andreas Liebl; Enrique Romero; Henriette Mersebach; Patrik Dykiel; Rolf Jorde
Journal:  Diabetes Care       Date:  2011-02-01       Impact factor: 19.112

9.  New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

Authors:  G B Bolli; M C Riddle; R M Bergenstal; M Ziemen; K Sestakauskas; H Goyeau; P D Home
Journal:  Diabetes Obes Metab       Date:  2015-02-12       Impact factor: 6.577

10.  Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

Authors:  Christine Clar; James Alexander Gill; Rachel Court; Norman Waugh
Journal:  BMJ Open       Date:  2012-10-18       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.